Global Markets Direct's, 'General Anxiety Disorder - Pipeline Review, H2 2014', provides an overview of the General Anxiety Disorder's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for General Anxiety Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for General Anxiety Disorder and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Full Report Details at
- http://www.fastmr.com/prod/910800_general_anxiety_disorder_pipeline_review_h2_2014.aspx?afid=101
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
* The report provides a snapshot of the global therapeutic landscape of General Anxiety Disorder
* The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
* The report reviews key players involved in the therapeutics development for General Anxiety Disorder and enlists all their major and minor projects
* The report summarizes all the dormant and discontinued pipeline projects
* A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
* Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
* A detailed assessment of monotherapy and combination therapy pipeline projects
* Coverage of the General Anxiety Disorder pipeline on the basis of target, MoA, route of administration and molecule type
* Latest news and deals relating related to pipeline products
Reasons to Get this Report
* Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
* Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
* Develop strategic initiatives by understanding the focus areas of leading companies
* Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder
* Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
* Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned in this Report: Edgemont Pharmaceuticals, LLC, H. Lundbeck A/S, Rottapharm SpA
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
General Anxiety Disorder Overview
Therapeutics Development
Pipeline Products for General Anxiety Disorder - Overview
Pipeline Products for General Anxiety Disorder - Comparative Analysis
General Anxiety Disorder - Therapeutics under Development by Companies
General Anxiety Disorder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Unknown Stage Products
General Anxiety Disorder - Products under Development by Companies
General Anxiety Disorder - Companies Involved in Therapeutics Development
Edgemont Pharmaceuticals, LLC
H. Lundbeck A/S
Rottapharm SpA
General Anxiety Disorder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
EDG-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EDG-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itriglumide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tedatioxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vortioxetine hydrobromide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
General Anxiety Disorder - Recent Pipeline Updates
General Anxiety Disorder - Dormant Projects
General Anxiety Disorder - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for General Anxiety Disorder, H2 2014
Number of Products under Development for General Anxiety Disorder - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Unknown Stage Development, H2 2014
Full Table of Contents is available at:
-- http://www.fastmr.com/prod/910800_general_anxiety_disorder_pipeline_review_h2_2014.aspx?dt=t&afid=101
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
read full article